Author:

RJ Hamster

Thursday’s Watchlist: See Why (CTXR) Just Hit Tomorrow’s Radar

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Paul Prescott Just Put Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) On Tomorrow’s Watchlist—Thursday, March 5, 2026

Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly

To Your Phone. Up To 10X Faster Than Email.

My Full Coverage On (CTXR) Will Start Early

Pull Up (CTXR) Before Tomorrow Morning…

March 4, 2026

Thursday’s Watchlist | See Why (CTXR)Just Hit Tomorrow’s Radar

Dear Reader,

A major shift is unfolding across biotech right now—and it’s changing how quickly a little-known company can move from development headlines to real commercial traction.

For years, the biggest moments in this space centered on trial readouts and FDA decisions.

But the story changes when a company proves it can do what most never reach: launch, distribute, and start generating real revenue.

That transition is rare, difficult, and often the moment broader market attention begins to build.

And today, one name just checked an important box that the Street tends to watch closely.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) recently reached a significant inflection point, reporting its first-ever product revenue following a major year-end launch.

With a pipeline aimed at large, high-value medical markets with significant unmet need—and a newly commercialized oncology asset—the company is positioning itself as an increasingly relevant player across critical care and oncology.

That’s why (CTXR) will be topping our watchlist tomorrow morning—Thursday, March 5, 2026.

But keep in mind, (CTXR) has less than 22M shares listed as available to the public. When companies have small public floats like this, the potential exists for big moves if demand begins to shift.

Right now, (CTXR) is sitting below $1 and appears to be flying under the radar of many screens.

On the analyst front, Jason Kolbert of D. Boral Capital recently reiterated a $6 target, which suggests over 600% upside potential from the current $0.80 range.

His view reflects the value of the company’s oncology ownership and the potential impact of late-stage programs like Mino-Lok as they progress through remaining regulatory steps.

Now let’s take a closer look at what (CTXR) has in hand today—and why the combination of a newly launched asset and late-stage programs has caught our attention.

A Late-Stage Platform With Commercial Momentum

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceuticalleader focused on developing and commercializing first-in-class critical care products.

The company’s strategy centers on high-value, proprietary formulations that address specific gaps in the current healthcare system, particularly in oncology and infectious diseases.

Currently, (CTXR) holds an approximately 74.8% ownership stake in its oncology subsidiary, which recently reached a pivotal commercial turning point.

The company’s focus is on “first-in-class” solutions, meaning they are not merely seeking to improve upon existing treatments but are aiming to provide the first FDA-approved prescription options for specific indications.

This distinctive approach allows (CTXR)to operate in markets with limited competition and high barriers to entry.

In December 2025, the company’s oncology subsidiary officially launched LYMPHIR, a targeted immunotherapy designed for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).

This launch represents the culmination of years of development and marks the transition of (CTXR) from a pure research entity into a revenue-generating company.

Beyond oncology, the company maintains a robust pipeline featuring Mino-Lok, a solution for catheter-related infections, and Halo-Lido, a topical treatment for hemorrhoids.

By focusing on therapeutic areas with limited competition, (CTXR) aims to capture significant shares of niche but lucrative medical markets.

The leadership team, bolstered by decades of experience in the pharmaceutical space, has systematically navigated the regulatory landscape to bring these products to the doorstep of commercialization.

Commercial Execution and Pipeline Expansion

The primary driver for (CTXR) at the start of 2026 is the commercial rollout of LYMPHIR. In February 2026, the company announced it had generated $3.9M in revenue from initial sales in December 2025 alone.

This rapid start suggests a strong initial uptake in the medical community for this CTCL treatment.

The oncology subsidiary estimates the addressable U.S. market for LYMPHIR to be over $400M, providing a substantial runway for growth as the product gains wider adoption among oncologists.

This revenue stream is critical as it provides a proof-of-concept for the company’s ability to market and sell complex biologics effectively.

Market Landscape And Industry Trends

The oncology landscape continues to shift toward targeted immunotherapies that aim to deliver strong efficacy with fewer side effects than traditional chemotherapy.

LYMPHIR aligns with this trend as a targeted approach in a treatment-experienced patient population.

At the same time, critical care—particularly hospital-acquired infections—remains an area where better solutions are still needed.

(CTXR) is addressing this through Mino-Lok, which is designed to salvage central venous catheters in patients with bloodstream infections. Today’s standard of care often requires painful and costly catheter removal and replacement.

By offering a catheter-salvage approach, Mino-Lok is positioned within a market the company cites as exceeding $2B globally, including over $1B in the U.S.

The economic incentive for hospitals to adopt Mino-Lok is clear: reducing the number of surgical procedures and the length of hospital stays. This alignment of patient outcomes and hospital economics is a cornerstone of the (CTXR) business model.

As healthcare systems worldwide look to optimize costs while improving care, Mino-Lok stands out as a high-value asset that could redefine the standard of care for millions of patients annually.

Competitive Positioning and Recent Operational Achievements

(CTXR) has secured a formidable position by targeting “orphan” indications and niche medical needs that larger pharmaceutical companies often overlook.

This strategy has led to the successful completion of a pivotal Phase 3 trial for Mino-Lok, which met both its primary and secondary endpoints.

Meeting these endpoints in a Phase 3 trial is a significant de-risking event for the company, as it demonstrates clinical efficacy and safety at a scale required for FDA approval.

In addition to its clinical successes, (CTXR) has demonstrated savvy financial management. In February 2026, the company secured $3.8M in non-dilutive capital through the New Jersey Economic Development Program.

This program allows technology and life sciences companies to sell their net operating losses and research and development tax credits for cash.

By utilizing this program, (CTXR) has been able to fund its continued execution without diluting existing shareholders, a move that reflects a commitment to long-term value creation.

Pipeline and Product Roadmap Drivers

While LYMPHIR and Mino-Lok are the current headliners, the potential of Halo-Lido should not be underestimated.

Targeting the symptomatic relief of hemorrhoids, this formulation addresses a massive patient population.

Over 10M people in the U.S. report symptoms, yet there is a glaring absence of FDA-approved prescription products that combine a corticosteroid and an anesthetic.

(CTXR) completed a Phase 2b trial for this program in 2023 and is currently working with the FDA to outline the next steps for a Phase 3 study.

The company’s roadmap is clear:

Maximize the commercial rollout of LYMPHIR via its oncology subsidiary.
Advance Mino-Lok through the final stages of the NDA process with the FDA.
Initiate Phase 3 trials for Halo-Lido to capture the massive outpatient market.

This three-pronged approach ensures that (CTXR) has multiple paths to significant valuation growth over the next 12 to 24 months.

Each program targets a different segment of the healthcare market, providing a balanced portfolio that mitigates the risks inherent in any single drug development program.

Financial Position and Management Team

Financially, (CTXR) is in a transition phase, moving from heavy R&D spending to a model supported by product sales.

As of its fiscal year 2025 report, the company has focused on maintaining a lean operational structure while directing resources toward its most promising assets.

The leadership team is a key component of the company’s strength. Leonard Mazur, Chairman and CEO, is a prominent figure in the pharmaceutical industry with a track record of building successful companies and executing high-value exits. Myron Holubiak, Vice Chairman, previously served as President of Roche Laboratories, bringing top-tier institutional knowledge to this agile organization.

7 Reasons Why (CTXR) Will Be Topping Our Watchlist Tomorrow Morning—Thursday, March 5, 2026…

1. Small Float: fewer than 22M shareslisted as available to the public means (CTXR) can react quickly when demand begins to build.

2. Analyst Target: coverage from D. Boral Capital includes a reiterated $6 target, placing (CTXR) at levels that suggest more than 600% upside potential from its recent $0.80 range.

3. Commercial Launch: a major milestone arrived when LYMPHIR became commercially available in December 2025, marking the shift of (CTXR) into a revenue-generating company.

4. First Revenue: early commercialization progress has begun as (CTXR) reported $3.9M from initial LYMPHIR sales following its December 2025 launch.

5. Phase 3 Success: strong clinical data was established after the Mino-Lok program met both primary and secondary endpoints in a pivotal Phase 3 trial tied to catheter-related infections.

6. Large Markets: major healthcare demand areas are being addressed as (CTXR) pursues indications tied to a $400M CTCL market and a catheter infection market exceeding $2B globally.

7. Pipeline Depth: multiple late-stage programs remain in motion with LYMPHIR commercialization underway while (CTXR) advances Mino-Lok regulatory steps and Halo-Lido Phase 3 planning.

Pull Up (CTXR) Before Tomorrow Morning…

Taken together, the pieces surrounding (CTXR) create a story worth paying attention to. The company has already crossed an important threshold with the commercial launch of LYMPHIR and the first reported revenue tied to that rollout.

At the same time, fewer than 22M shares listed as available to the public means activity can become more reactive when attention increases.

Add in a reiterated $6 analyst targetfrom D. Boral Capital, recent Phase 3 success for the Mino-Lok program, and additional late-stage work underway with Halo-Lido, and it becomes clear why (CTXR) could start to appear on more screens.

Beyond those developments, the company is working in areas tied to meaningful healthcare demand—from a CTCL market estimated around $400Mto catheter-related infection treatment markets that exceed $2B worldwide.

With commercialization now underway and several programs advancing toward their next milestones, the coming months could prove to be an important period for (CTXR).

We will have all eyes on (CTXR)tomorrow morning.

Take a look at (CTXR) before you call it a night.

Also, keep a lookout for my morning update.

Have a good night.

Sincerely,

Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter

Street-Ideas.com (“Street-Ideas” or “SI” ) is owned by 147 Media LLC, a single member limited liability company. Data is provided from third-party sources and SI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.

Pursuant to an agreement between 147 Media LLC and TD Media LLC, 147 Media LLC has been hired for a period beginning on 03/04/2026 and ending on 03/05/2026 to publicly disseminate information about (CTXR:US) via digital communications. Under this agreement, TD Media LLC has paid 147 Media LLC eight thousand seven hundred fifty USD (“Funds”). To date, including under the previously described agreement, 147 Media LLC has been paid thirty three thousand seven hundred fifty USD (“Funds”). These Funds were part of the fifty five thousand USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.

Neither 147 Media LLC, TD Media LLC and their member own shares of (CTXR:US).

Please see important disclosure information here: https://street-ideas.com/disclosure/ctxr-C7PxT/#detailsStreet Ideas6586 W Atlantic AveUnit #2086Delray Beach, FL 33446Unsubscribe Update Profile | Constant Contact Data NoticeSent by paul@street-ideas.com

RJ Hamster

Last Chance for Lifetime Access

Zacks | Our Research. Your Success.

Deadline at Hand for Zacks’ Greatest Investment Value

Zacks Member,

This is a final reminder to take advantage of an exclusive opportunity before the deadline at midnight tonight.

Until then, you can claim our highest level of membership at a fraction of its value —the lowest cost available.

As I reported earlier today, this is flat-out the best value we offer at Zacks in terms of how much you get for how little it costs.

Time’s running short, so let me sum up the key points that make this arrangement so special:•A deep discount on your one-time membership payment. The temporary savings are unbelievable and there will never be extra fees or add-on charges.•Permanent access to the real-time buys, sells, and market commentaryof all Zacks’ private portfolio services, which closed 286 double- and triple-digit winners in 2025 alone. Recent gains have reached as high as +198.4%, +499.3%, +627.5%, and even +2,027.7%.¹ While not every pick will be a winner, just one could more than cover the cost of your membership.•Money-Back Satisfaction Guarantee.If the service has not exceeded your expectations, you can cancel up to 90 days after your one-time payment and receive a full refund for it.•Unprecedented Money-Back 3-year Performance Guarantee. If we don’t help you beat the market, we’ll refund your subscription.

Click the button below for your chance to make money and build wealth today and for many years to come.

I urge you not to miss this brief window of opportunity. The deadline is Wednesday, March 04 – midnight tonight.▶ See Stocks Now

All the Best,

Kevin Matras, EVP

¹The results listed above are not (or may not be) representative of the performance of all selections made by Zacks Investment Research’s newsletter editors and may represent the partial close of a position. Access grants you a comprehensive list of all open and closed trades.

This free resource is being sent by Zacks.com. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks “Terms of Service”. https://www.zacks.com/terms_of_service

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research is not a licensed securities dealer, broker or U.S. investment adviser or investment bank.

The Zacks #1 Rank Performance covers the period beginning on January 1, 1988 through February 2, 2026. The performance is the equal weighted performance of a hypothetical portfolio consisting of stocks with a Zacks Rank of #1 that was rebalanced monthly from January 1988 through December 2013 and weekly from 12/31/13 through Monday’s open on February 2, 2026. For each stock with a Zacks Rank #1 at the beginning of the month, the total return during the month was calculated as the % change in the price of the stock from the closing price of the prior month to the closing price of the current month plus any dividends received during the month. The monthly individual stock returns were then averaged to determine the portfolio return for the month. For each stock with a Zacks Rank #1 at the beginning of the week, the total return during the week was calculated as the % change in the price of the stock from the opening price for the week to the opening price of the next week plus any dividends received during the week. The weekly individual stock returns were then averaged to determine the portfolio return for the week. If no month-end price or week end open price was available for a stock, it was not included in the portfolio return for the month or the week. The monthly and weekly returns were compounded to arrive at the annual returns. The annualized return is the annual return that, had it been achieved in each year or portion of a year, would have compounded to create the total return over the full time period. These returns are based on the list of Zacks Rank #1 Stocks that was available to clients of Zacks as of the beginning of the month, when returns were calculated monthly, or as of the beginning of the week when returns were calculated weekly. These returns are higher than the returns an investor could achieve investing real money in a portfolio of Zacks Rank #1 stocks because the returns of the hypothetical Zacks Rank #1 portfolio exclude a number of costs, including commissions incurred for trading, the average bid ask spread, the price impact of the trading and, prior to 2013, in those months when the end of the month fell on Friday, Saturday or Sunday, the overnight return from the month end close to the open on the next trading day. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance_disclosure for information about the performance numbers displayed above.

Zacks Emails
If you would prefer to not receive future profit-producing emails from Zacks.com the primary purpose of which is the commercial advertisement or promotion of a commercial product or service, then please click here and confirm your request. If you have trouble with the unsubscribe link, please email support@zacks.com.

Zacks Investment Research
101 N Wacker Drive, Floor 15
Chicago, IL 60606

RJ Hamster

Iran Missile Fired Toward NATO Ally Turkey; Pentagon Dismisses…

Serious question, folks…
— Read on istandforfreedom.com/iran-missile-nato-turkey/

RJ Hamster

REVEALED: Something Big Happening Behind White House Doors

MARCH 04, 2026 | READ ONLINE

Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.

WHITE HOUSE INSIDER BUCK SEXTON:
“TRUMP’S NEXT MOVE WILL
SHOCK THE WORLD”

Dear Reader,

I just returned from a private interview at the Biltmore hotel…

Where I shared a chilling prediction regarding a major plan currently developing inside the Trump administration.

See, I have had direct access to top-level defense and national security officials… Pete Hegseth, Tulsi Gabbard, Marco Rubio and others…

Which is why I was recently invited to a sit-down meeting with President Trump and Vice President Vance inside the West Wing of the White House.

And what I learned gave me the chills…

That’s why, today, I’ve decided to give a rare interview breaking down something I believe every American needs to hear – especially investors.

It’s not about tariffs, crypto, or the Fed. Or anything else you’re hearing about ad nauseam from the mainstream press right now.

It’s about a radical move I believe Trump is going to make any day – one that could shock the world.

Because I believe it could single-handedly reshape the global order… dramatically increase U.S. power… and trigger a massive American market boom the likes of which we haven’t seen in 75 years.

President Trump himself said this is all about one thing…

Igniting what he calls “the most extraordinary boom the world has ever seen.”

This is a rare opportunity, folks.

And I’m bringing it to you on a silver platter… long before anyone else gets wind of it. Take it while you can. Because once this story and opportunity hits the mainstream, it could be too late to act.

You deserve this…

Get the details here now.

Sincerely,

Buck Sexton
Editor, Paradigm Press

5 Stocks Racing Ahead as AI Supercharges Robotics

Authored by Ryan Hasson. First Published: 3/2/2026.

KEY POINTS

Artificial intelligence is accelerating robotics innovation, enabling faster training, greater autonomy, and real-time adaptability across industries.
Companies like Tesla, NVIDIA, Deere, Teradyne, and Intuitive Surgical are embedding AI directly into machines, compressing development cycles and expanding real-world applications.
As AI scales globally, robotics is shifting from incremental automation to intelligent systems, creating long-term structural growth opportunities across multiple sectors.
Special Report: Silver records prices are great. Monthly income is better (From Investors Alley)

Robotics has steadily gained traction over the past decade, but the last five years have marked a clear inflection point. Adoption across industrial, defense, healthcare, logistics, and even consumer applications has accelerated meaningfully. The primary catalyst behind this shift is artificial intelligence.

AI is not just enhancing robotics; it is fundamentally redefining it.

SILVER $309? (AD)

Silver: 20% + 68%

Tim Plaehn just found a Silver ETF that delivers monthly income (up to 20% in annual distributions) plus share appreciation (68% in 5 months). The precious metal has become one of the best investments for growth AND income right now.Click here and start to collect in the next 30 days.

Machine learning, computer vision, and generative AI are transforming robots from rigid, pre-programmed machines into adaptive systems that can learn, reason, and operate autonomously. Breakthroughs that once took years of incremental improvement are now occurring in much shorter timeframes.

Generative AI lets robots train in simulated environments at high speed instead of relying solely on physical trial and error. Developers can expose machines to millions of virtual scenarios in a fraction of the time it would take in the real world. Natural language interfaces also allow workers to instruct machines conversationally, dramatically reducing deployment friction.

In short, AI is acting as an accelerant across the robotics landscape, pushing both capability and commercialization forward faster. These five stocks are advancing more rapidly as a direct result of AI integration.

Tesla: From Autonomous Vehicles to Humanoid Robots

Tesla (NASDAQ: TSLA) may be best known as an electric vehicle manufacturer, but at its core it is arguably one of the world’s most visible consumer-facing robotics companies.

Its autonomous vehicles are essentially mobile robots operating in uncontrolled, real-world environments. Tesla’s Full Self-Driving system relies on neural networks trained on billions of miles of driving data. That same AI backbone powers Optimus, its humanoid robot initiative.

Optimus is designed to handle repetitive, dangerous, or labor-intensive tasks across factories, warehouses, and eventually households. It uses computer vision, reinforcement learning, and Tesla’s custom AI chips to interpret surroundings and navigate complex environments. The real breakthrough is as much in the software stack that lets Optimus learn and improve over time as it is in the mechanical engineering.

CEO Elon Musk has described Optimus as potentially more transformative than Tesla’s vehicle business in the long run. The company is targeting eventual mass production in the millions of units annually, with a projected consumer price point between $20,000 and $30,000.

Tesla recently announced plans to wind down production of its high-end Model S and Model X lines to free up factory capacity for a dedicated Optimus assembly line. That strategic pivot signals confidence that AI-powered robotics could become a central pillar of the company’s future growth.

NVIDIA: The Computing Backbone of Robotics

NVIDIA (NASDAQ: NVDA) is the most obvious AI beneficiary, but its impact on robotics runs deeper than headline GPU demand suggests.

Advanced robotics requires massive computing resources for perception, localization, mapping, and decision-making. Without high-performance processors capable of running complex neural networks in real time, modern robotics would stall.

NVIDIA’s Jetson platform is purpose-built for edge AI and is widely deployed in robots, drones, and autonomous systems. These modules process visual, spatial, and sensor data locally, enabling low-latency decision-making—critical in environments where split-second reactions matter.

Beyond hardware, NVIDIA’s Isaac robotics development platform lets engineers simulate robotic systems in photorealistic virtual environments. Developers can train robots in simulation before deploying them in the physical world, accelerating innovation cycles while lowering risk and cost.

As robotics systems grow more intelligent and autonomous, NVIDIA remains a foundational infrastructure provider. It is not simply participating in the growth of robotics; it is enabling it.

Deere & Company: Smart Farming at Scale

Deere & Company (NYSE: DE) might surprise some investors on a robotics list, but the agricultural leader has quietly transformed into a technology-driven automation company.

Labor shortages, rising input costs, and the need for greater efficiency have pushed agriculture toward autonomy. Deere’s fully autonomous 8R tractor can operate without a driver, using AI-powered computer vision and advanced GPS guidance to navigate fields with precision.

After acquiring Blue River Technology, Deere launched its See & Spray system, which uses machine learning to distinguish crops from weeds in real time. Instead of blanket herbicide spraying, the system applies chemicals only where needed, reducing usage and improving environmental efficiency.

AI also powers Deere’s broader ecosystem through the John Deere Operations Center, which aggregates farm data and delivers predictive analytics to optimize planting, harvesting, and maintenance decisions.

The company has effectively shifted from a heavy equipment manufacturer to a data-driven automation platform for agriculture. As AI models improve, productivity gains across farming operations could accelerate, reinforcing Deere’s long-term positioning.

Teradyne: Testing the AI Revolution

Teradyne (NASDAQ: TER) operates at a critical junction of semiconductor complexity and industrial automation. As AI chips become more powerful, dense, and performance-sensitive, testing requirements intensify.

Teradyne’s automated test equipment validates advanced semiconductors for data centers, autonomous systems, and robotics applications.

AI-driven demand has become a primary growth driver. In Q4 2025, the company reported EPS of $1.80, well above consensus, while revenue rose nearly 44% year over year to $1.08 billion. AI-related demand, including data center expansion, accounted for a majority of quarterly revenue.

Beyond semiconductor testing, Teradyne owns collaborative robotics businesses that manufacture industrial robotic arms and mobile robots. These systems increasingly incorporate AI to improve flexibility in factories and logistics centers.

With AI adoption scaling across industries, both chip testing and AI-enabled robotics solutions position Teradyne as a beneficiary of the broader automation wave—a classic picks-and-shovels play.

Intuitive Surgical: AI in the Operating Room

Intuitive Surgical (NASDAQ: ISRG) is a pioneer in robotic-assisted surgery and remains the global leader in minimally invasive procedures.

Its da Vinci Surgical System has already transformed surgical precision by giving physicians enhanced visualization, dexterity, and control. Now, AI is deepening that advantage.

Rather than operating solely as a hardware manufacturer, Intuitive is building an intelligent surgical ecosystem. AI algorithms analyze intraoperative data in real time, enhance imaging clarity, and provide insights that help surgeons make more precise decisions.

The company’s Ion endoluminal system, for example, uses AI-powered computer vision to navigate to difficult-to-reach lung nodules, compensating for discrepancies between pre-operative imaging and live anatomy. This improves diagnostic accuracy and patient outcomes.

As the installed base of robotic systems grows globally, the accumulation of surgical data strengthens Intuitive’s AI models. That flywheel effect could widen its competitive moat over time.

The Acceleration Effect

Robotics is not new. What is new is the velocity of innovation.

AI is compressing development timelines, improving adaptability, and broadening commercial use cases across nearly every sector. Whether in autonomous vehicles, agriculture, semiconductor testing, industrial automation, or operating rooms, AI is acting as a multiplier.

For investors, the theme is not simply robotics adoption but robotics acceleration driven by AI integration.

These five companies sit at the forefront of that shift, advancing faster because intelligence is now embedded directly into the machines themselves.

This ad is sent on behalf of Paradigm Press, LLC, at 1001 Cathedral St., Baltimore, MD 21201. If you’re not interested in this opportunity from Paradigm Press, LLC, please click here to remove your email from these offers.

Update your email preferences or unsubscribe here

345 N Reid Place #620
Sioux Falls, SD 57106, United StatesPowered by beehiiv Terms of Service

RJ Hamster

thetradersintelligence.com

thetradersintelligence.com

RJ Hamster

Royalty Riches

Two Nobel Prize winners warn of this once-in-a-generation wealth shift…
— Read on porterandcompanyresearch.co/mrln/

RJ Hamster

🦉 The Night Owl Newsletter for March

Unsubscribe Silver $309? (From Investors Alley)

Uber and Joby Aviation Team Up: Game Changer or Hype?

Written by Jordan Chussler

An estimated 110 million Americans are stuck in rush hour traffic every day, with drivers in highly congested cities losing as much as 100 hours per year to being stuck in traffic jams.

That issue does not appear to be getting any better, either. Traffic congestion is on the rise in 70 of the 100 largest U.S. cities. But if U.S. Federal Aviation Administration (FAA) approval works out for Joby Aviation (NYSE: JOBY), help could be on its way.

The aerospace company is focused on developing electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility.

Joby’s core mission is to provide zero-emission aerial rideshare services, combining the speed of helicopters with the cost efficiency and environmental benefits of electric propulsion.

If that sounds a lot like the aviation version of what Uber Technologies (NYSE: UBER) offers, that’s because it is.

That alignment has played a central role in the two companies announcing the formation of a strategic partnership last month.

According to a press release, Uber Air will be powered by Joby, “giving riders a first look at how they’ll be able to book Joby Aviation all-electric air taxis directly in the Uber app.”

That announcement came on the same day that Joby reported full-year and Q4 2025 earnings. After gaining nearly 52% over the past year, here is what investors will want to know about the company that is transitioning from its pre-revenue stage.

Q4 Earnings and Revenue Beats Stress the Need for Patience

When Joby reported on Feb. 25, it beat on the top and bottom lines. Earnings per share (EPS) came in at -14 cents, beating analyst expectations of -20 cents, while revenue of $30.84 million easily surpassed analyst expectations of $16.88 million.

But with a trailing EPS of -$1.14, Joby Aviation’s full-year earnings are expected to decrease next year, from -69 cents to -70 cents per share.

The Q4 revenue beat can largely be attributed to Joby’s acquisition of Blade Air Mobility’s passenger business, which fueled year-over-year revenue growth of nearly 5,507%.

According to the company, “the acquisition provides Blade’s established network of terminals and loyal flyers in key markets like New York and in Southern Europe, positioning Joby for a faster entry into commercial service with its quiet [eVTOL] aircraft once certified.”

The operative term, however, is “once certified.” Joby has yet to begin commercial eVTOL operation as it continues to navigate the FAA approval procedures.

Joby’s Portability Timeline Is Concerning

The company is currently in the fourth stage of the five-stage FAA Type Certification process for its eVTOL aircraft. Joby is aiming for a launch of commercial services at some point in 2026, once the FAA confirms its aircraft.

But a key milestone for the company will include Part 141 flight academy approval, Part 145 maintenance certification, and testing of FAA-conforming components. As a result, Joby is not expected to reach profitability until 2029 to 2031 as it invests heavily in scaling manufacturing and obtaining FAA certification. That has resulted in an annual cash burn rate of approximately $500 million.

In his earnings call comments, founder and CEO JoeBen Bevrit provided a glimpse of the company’s near-term future, saying it is “seeing unprecedented demand” for its forthcoming eVTOL services from governments, real estate developers, and infrastructure partners around the globe.

Bevrit added that Joby plans “to carry our first passengers this year in the UAE as part of our six-year exclusive access to the Dubai market, and here in the U.S., we expect the government’s eIPP program to provide us with the opportunity to demonstrate our service in several locations also this year.”

While the profitability timeline may be concerning to some prospective investors, the company is scaling both production and balance sheet strength at an impressive rate. On Jan. 7, Joby announced that it signed an agreement to acquire a second, 700,000-square-foot manufacturing facility in Dayton, Ohio, for $61.5 million to expand its eVTOL production capabilities. The facility will support it in reaching its 2027 production goals, including manufacturing four eVTOL aircraft per month.

Buyer Beware: Analysts Have Mixed Takes on Joby’s Future

Based on the nine analysts covering JOBY stock, it receives a consensus Reduce rating, with only two analysts assigning it a Buy rating. However, analysts’ average 12-month price target of $13.81 suggests more than 34% potential upside from where shares are currently trading.

Institutional ownership remains tepid at less than 53%, but inflows of $1.31 billion over the past 12 months have easily surpassed outflows of more than $722 million. That said, institutional buying has dramatically slowed down since hitting its all-time high during Q4 2024, falling from $1.03 billion to just $273 million in Q4 2025.

Meanwhile, current short interest—which stands at 12.77%—warrants ongoing monitoring. That figure equates to nearly 79 million shares of the more than 911 million shares outstanding, valued at $779 million, though that dollar amount is down from the record $1.06 billion worth of shares that were shorted in October 2025. READ THIS STORY ONLINE

Why Q4 Could Destroy Your Wealth (Ad)

Dr. Martin Weiss, who has called major financial events long before others, now warns of a $112 trillion crisis hiding in America’s “basement.” It’s not mortgages again. It’s an unseen danger destabilizing one of our most critical sectors. The fuse is lit for late 2026. See the undeniable evidence for yourself and put your protection plan in place.CLICK HERE TO WATCH THE URGENT FORECAST NOW.

CrowdStrike Beats, But AI Concerns Persist

Written by Chris Markoch

CrowdStrike Holdings Inc. (NASDAQ: CRWD) ticked higher on March 4, the day after it reported earnings, building on prior momentum.

The stock got a pre-earnings bump after the United States and Israel began a military campaign against Iran. From the opening of trading on March 2 to the close on March 3, CRWD stock rose approximately 6% amid volatility. This was a move in sympathy with defense and cybersecurity stocks. Since the conflict began, there have been many voices, including JPMorgan Chase chief executive officer (CEO) Jamie Dimon, warning about an escalated threat of cyberattacks in the United States.

That’s not news to corporations or consumers. Cybercrime is expected to cost businesses over $10 trillion in 2026, up from around $6 trillion in 2021. That number may be too low if analysts are correct in their estimates of the threat from agentic AI.

Earnings and Guidance Were Solid, But Confirmed Concerns

CrowdStrike delivered a solid earnings report after the market closed on March 3. The numbers weren’t eye-popping, but the cybersecurity company did post a slight beat on the top and bottom lines.

Revenue of $1.31 billion was higher than the $1.3 billion that was forecast. A similar story emerged on the bottom line. Adjusted earnings per share (EPS) came in at $1.12, beating expectations for EPS of $1.10. The quarter also set records for net new annual recurring revenue (ARR), operating income, and free cash flow.

These metrics carry real weight for a company like CrowdStrike, which investors largely evaluate on the quality of its recurring revenue. Ending ARR reached $5.25 billion, up 24% year-over-year (YOY), while net new ARR surged 47% to $331 million.

CrowdStrike expects first-quarter revenue of $1.36 billion to $1.364 billion, and first-quarter adjusted earnings of $1.06 to $1.07 per share. For full-year fiscal 2027 revenue, it projects $5.87 billion to $5.93 billion, as well as adjusted earnings of $4.78 to $4.90 per share.

The guidance was essentially in line with analyst expectations. It was enough to satisfy, but perhaps not enough to silence the skeptics asking bigger structural questions about AI and pricing.

Agentic AI: Friend or Foe?

From November into January, investors could say the concern about CRWD stock, like many technology stocks, centered on its valuation. Since then, another concern has emerged. As agentic AI expands, analysts are concerned about the pricing models for software stocks, particularly those like CrowdStrike that trade at premium valuations.

Their concerns can be summarized like this. If AI agents can increasingly automate threat detection and response tasks that once required expensive, layered software subscriptions, enterprises may demand fewer modules or push back on pricing. That pressure is particularly acute for a company like CrowdStrike, which commands a significant revenue-per-customer premium built on its expanding Falcon platform.

Why AI Could Expand Cybersecurity Demand and Strengthen CrowdStrike’s Platform

The bearish AI argument, while legitimate as a long-term concern, may be premature. The World Economic Forum predicts cybersecurity spending will reach $520 billion by the end of 2026, more than double the amount spent just five years ago. The threat landscape is evolving, and AI is as much an accelerant for attackers as it is a tool for defenders.

That’s precisely where CrowdStrike’s architecture becomes a meaningful advantage rather than a liability. The Falcon platform was built AI-native from the ground up, which positions it differently from legacy vendors scrambling to bolt on AI capabilities after the fact. The company’s Charlotte AI and AgentWorks capabilities are designed specifically to automate threat detection and response at the speed and scale that modern enterprises require, including the protection of AI agents themselves from adversarial exploitation.

The platform’s breadth is also working in its favor. Fifty percent of subscription customers now use six or more modules, with 34% using seven or more and 24% using eight or more. That level of platform consolidation creates deep switching costs that pricing pressure alone is unlikely to unravel.

The company’s Falcon Flex program, which lets customers shift ARR across modules as needs evolve, has been particularly effective at driving adoption. The company now reports over 1,600 Flex customers and $1.69 billion in ending ARR from Flex accounts, up more than 120% YOY. Gross retention held at 97% across all four quarters of fiscal 2026, underscoring that customers aren’t leaving even in a more cautious spending environment.

Technical Outlook for CRWD Stock

The consensus price target for CRWD stock as of this writing is $508.85. That would be a gain of around 27%. Analysts remain bullish on the stock, but many have lowered their price targets since the report.

In the short term, the technical picture remains challenged. CRWD is trading at roughly $397, well below both its 50-day moving average near $435 and its 200-day moving average near $469. Both moving averages are sloping downward, which is a meaningful headwind for any sustained recovery. The stock needs to reclaim the 50-day moving average convincingly before the current trend can be considered anything other than bearish.

The longer-term picture is more constructive. The $340-$360 zone appears to have established a meaningful support base. A measured move back toward the $420-$435 range would test the declining 50-day, a reasonable near-term target. A breakout above that level would shift the technical narrative considerably. For now, CRWD looks like a stock in recovery mode: the worst may be behind it, but patience is required before the trend turns decisively higher. READ THIS STORY ONLINE

Silver $309? (Ad)

Silver: 20% + 68%

Tim Plaehn just found a Silver ETF that delivers monthly income (up to 20% in annual distributions) plus share appreciation (68% in 5 months). The precious metal has become one of the best investments for growth AND income right now.CLICK HERE AND START TO COLLECT IN THE NEXT 30 DAYS.

GitLab Sell-Off Overdone: AI and Cash Flow Signal a Rebound

Written by Thomas Hughes

Fears of slowing growth and AI disruption sent Gitlab (NASDAQ: GTLB) shares to long-term lows in early March, and the sell-off, overdone to begin with, has reached ultra-deep value levels, presenting an irresistible opportunity.

While AI-related fears are affecting the near-term outlook, the company continues to grow and is well-positioned for the AI inference era. Its platform, along with newer products, embeds AI functionality throughout the software lifecycle, enabling efficiency and superior outcomes at every step while ensuring security, compliance, and governance standards are maintained.

Proof of its position and the strength of its outlook lies in its cash flow and balance sheet, which enabled the authorization of a share buyback. The company is cash flow positive despite aggressive investment, has a solid outlook for improvement, and plans to spend up to $400 million buying back shares.

This is worth approximately 10% of the post-release market cap, strengthening its already solid support base. Investors can expect GitLab to buy shares on price pullbacks, such as the one in early March, when GitLab shares hit record-low levels.

The balance sheet highlights a strong and strengthening capital positionand improving shareholder value. Current assets were up across all categories at year’s end, with cash and equivalents well-above liability levels. The company has no long-term debt, has total liabilities less than its equity, and equity increased by 27% for the year.

Valuation, Institutions, and Analysts Point to GTLB’s Robust Upside Potential

Gitlab’s shares could double from their March lows strictly on the strength of its earnings estimates. The forecasts imply a high-teens to low-20% compound annual growth rate (CAGR) through the middle of the next decade, putting the stock near 10x its 2035 consensus. In one scenario, it could rise by at least 100% to align with broad market averages, or by 200% or more to align with established blue-chip tech companies.

Proof of Gitlab’s value lies in its institutional and analyst trends. The institutions, including public and private capital, own approximately 95% of the stock and have been aggressively buying it up.

MarketBeat data reveal that they have been buying on balance for 13 consecutive quarters, with activity ramping in 2025 and again in early 2026.

This is a solid support base, likely to continue the trend in 2026, functioning a tailwind for stock prices once the rebound gains traction.

Analysts responded bearishly to GitLab’s fiscal Q4 2026 earnings report, but that was relative to a high bar. MarketBeat tracked half a dozen revisions with the first 12 hours of the release, including one downgrade, five price target reductions, and one affirmation, but the impact on sentiment trends was minimal.

The six ratings suggest a stronger rating than the broad Moderate Buy consensus, and the price targets, while falling at the low end of the range, average to just below the broad consensus, which suggests a 65% upside is possible.

Gitlab Offers Mixed Guidance After Strong Report

Gitlab has a solid fiscal year 2026 (FY2026) and Q4. The company reported $260.4 million in net revenue, up more than 23.2% year-over-year and 320 basis points better than the consensus. Strength was driven by large clients, with an 8% gain across the board, led by an 18% and 26% increase in large and mega-sized businesses. Net retention rate (NRR), a measure of penetration, was also strong at 118%, as was the forward-looking remaining performance obligation (RPO). It increased by 24% on a current basis and 20% overall, suggesting strong growth will continue in the upcoming quarters.

Margin news was also bullish. The company’s gross margin narrowed by 200 bps, but this was offset by improvements in operations quality. Adjusted operating margin improvedby 300 basis points to drive an accelerated 42.8% growth in operating income. The only bad news was that spending increases cut into profits, leaving the adjusted EPS and free cash flow down on a year-over-year (YOY) basis. That said, the adjusted earnings of 30 cents were 7 cents above forecasts, providing no reason to sell the stock.

Guidance, although mixed relative to consensus, was solid; the revenue forecast slightly missed expectations, and earnings were forecast to be strong. The company expects more than 17% revenue growth this year and wider margins, with the adjusted EPS target 250 bps above consensus and guidance likely to be cautious. The company revealed five initiatives to drive growth, including expanding the go-to-market presence, accelerating client acquisition, optimizing pricing/packaging, and executing its AI strategy. READ THIS STORY ONLINE

Have $500? Invest in Elon’s AI Masterplan (Ad)

What if you could claim a stake in what’s set to be the biggest IPO ever… starting with just $500?

Everyone is talking about Elon Musk’s SpaceX IPO.CLICK HERE TO GET THE DETAILS AND I’LL SHOW YOU HOW TO CLAIM YOUR STAKE…